Pitanium faces Nasdaq delisting

Sanmina targets $16B+ revenue in FY 2027 as it guides Q4 EPS of $3.05-$3.35

Opko outlines $560M-$585M 2026 revenue guidance while planning MDX3001 clinical start by end of 2026 or early 2027

3 Reasons SBH is Risky and 1 Stock to Buy Instead

2 Reasons to Like ELF (and 1 Not So Much)